


INNO-LiPA HBV

Maximize your treatment options with LiPA

Only valid for CE-marked assays.



The INNO-LiPA HBV family:

Select
LiPA

INNO-LiPA HBV Genotyping* CE
Identification of HBV Genotypes A to H

INNO-LiPA HBV DR v2* CE
Simultaneous detection of HBV Wild-type motif, lamivudine, telbivudine, emtricitabine, and adefovir resistance-associated mutations

INNO-LiPA HBV PreCore**
Simultaneous detection of HBV wild-type motif and mutations in the basal core promoter and precore region



INNOGENETICS®
BIOTECHNOLOGY FOR HEALTHCARE

* US: For Research Use Only. Not for use in diagnostic procedures.
** For Research Use Only. Not for use in diagnostic procedures.

INNO-LiPA HBV

INNO-LiPA HBV Genotyping



When genotyping, be confident:
Select LiPA

Proven performance in clinical trials

- As predictor of response to treatment¹
- Standardized method for new drug development²
- interferon/entecavir

Internationally standardized reference method

- Routinely used in at least 30 countries
- Preferred by key opinion leaders²
- Helps pinpoint treatment options for interferon or nucleos(t)ide analogs

Distinct advantage in detection of mixed infections

- Ultrasensitive diagnostic method
- Maximize information for treatment options

INNO-LiPA HBV DR v2



Minimize treatment failure, Maximize long-term HBV suppression:
Select LiPA

Proven performance in clinical trials

- Method of choice for HBV drug/resistance monitoring
- Key opinion leaders' first choice²

Continuous efforts to stay up to date for new key mutations

- Ongoing commitment for key mutation updates
- Most widely used standardized method

Earliest timepoint for upcoming genotypic breakthrough³

- Avoids clinical breakthrough (ALT peak)
- Monitor treatment compliance
- Provides cost-effective solutions

INNO-LiPA HBV PreCore*



Offers true HBeAg status:
Select LiPA

1. Janssen HLA, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-129.

2. Innogenetics publication overview available upon request.

3. Lampertico P, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005;42:1414-1419.



INNOGENETICS[®]
BIOTECHNOLOGY FOR HEALTHCARE

Registered office: INNOGENETICS NV
Technologiepark 6 - 9052 GENT - BELGIUM
Tel. +32-9-329-1329 - Fax +32-9-329-1775
www.innogenetics.com

Your Agent: _____